Page last updated: 2024-08-25

bexarotene and cyclin d1

bexarotene has been researched along with cyclin d1 in 6 studies

Research

Studies (6)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (50.00)	29.6817
2010's	3 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Biddle, A; Desai, NB; Dmitrovsky, E; Dragnev, KH; Memoli, V; Petty, WJ; Rigas, JR; Shah, S	1
Bissonnette, RP; Brown, PH; Kim, H; Lamph, WW; Seo, HS; Shen, Q; Uray, IP	1
Andersen, JB; Black, CC; Dmitrovsky, E; Dragnev, K; Feng, Q; Galimberti, F; Guo, Y; Hassel, BA; Liu, X; Memoli, V; Sekula, D; Sempere, LF; Shah, SJ	1
Bissonnette, RP; Brown, PH; Kim, HT; Lamph, WW; Li, Y; Shen, Q; Yan, B	1
Busch, AM; Cyrus, J; Dmitrovsky, E; Dragnev, KH; Erkmen, CP; Freemantle, SJ; Galimberti, F; Johnstone, D; Kurie, JM; Liu, X; Ma, T; Memoli, V; Nugent, W; Rigas, JR; Seltzer, M; Tsongalis, GJ; Waxman, S	1
Choi, CI; Janakiram, NB; Mohammed, A; Qian, L; Rao, CV; Steele, VE	1

Trials

2 trial(s) available for bexarotene and cyclin d1

Article	Year
Bexarotene and erlotinib for aerodigestive tract cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured	2005
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:6 Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured	2011

Article

Year

Bexarotene and erlotinib for aerodigestive tract cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cell Survival; Cyclin D1; Digestive System Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Head and Neck Neoplasms; Humans; Hypertriglyceridemia; Lung Neoplasms; Male; Middle Aged; Mouth Mucosa; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured

2005

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.

Cancer prevention research (Philadelphia, Pa.), 2011, Volume: 4, Issue:6

Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoblotting; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Transgenic; Middle Aged; Mouth Mucosa; Mutation; Necrosis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Survival Rate; Tetrahydronaphthalenes; Treatment Outcome; Tumor Cells, Cultured

2011

Other Studies

4 other study(ies) available for bexarotene and cyclin d1

Article	Year
Rexinoid-induced expression of IGFBP-6 requires RARbeta-dependent permissive cooperation of retinoid receptors and AP-1. The Journal of biological chemistry, 2009, Jan-02, Volume: 284, Issue:1 Topics: Anticarcinogenic Agents; Bexarotene; Cell Line, Tumor; Cyclin D1; Female; Gene Expression Regulation; Gene Knockdown Techniques; Genes, fos; Humans; Insulin-Like Growth Factor Binding Protein 6; Introns; Mammary Glands, Human; p300-CBP Transcription Factors; Proto-Oncogene Proteins c-jun; Receptors, Retinoic Acid; Response Elements; Retinoic Acid Receptor alpha; Retinoic Acid Receptor gamma; Retinoid X Receptor alpha; Tetrahydronaphthalenes; Transcription Factor AP-1	2009
UBE1L causes lung cancer growth suppression by targeting cyclin D1. Molecular cancer therapeutics, 2008, Volume: 7, Issue:12 Topics: Anticarcinogenic Agents; Bexarotene; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cycloheximide; Cytokines; Humans; Ki-67 Antigen; Lung Neoplasms; Models, Biological; Plasmids; Retinoid X Receptors; Tetrahydronaphthalenes; Ubiquitin-Activating Enzymes; Ubiquitins	2008
The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor. Breast cancer research and treatment, 2011, Volume: 128, Issue:3 Topics: Basic Helix-Loop-Helix Transcription Factors; Bexarotene; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA-Binding Proteins; Down-Regulation; Epithelial Cells; Gene Expression Regulation; Histone Deacetylases; Humans; Mammary Glands, Human; Models, Biological; Promoter Regions, Genetic; Tetrahydronaphthalenes; Transcription, Genetic	2011
Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice. Neoplasia (New York, N.Y.), 2012, Volume: 14, Issue:2 Topics: Adenomatous Polyposis Coli; Adenomatous Polyposis Coli Protein; Animals; Anticarcinogenic Agents; Bexarotene; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin D1; Cyclooxygenase 2; Cytokines; Drug Screening Assays, Antitumor; Female; Intestinal Mucosa; Intestinal Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Inbred C57BL; Oleic Acid; Retinoid X Receptor alpha; Tetrahydronaphthalenes; Triglycerides	2012